Key Takeaways
- • EQT-owned IVC Evidensia spent £34m over two years responding to a UK Competition and Markets Authority (CMA) investigation into veterinary sector pricing practices, with £10.6m incurred in the year to September 2025 alone, following £24m the prior year.
- • The CMA's March 2026 conclusion of its industry-wide veterinary sector review removes a significant regulatory overhang for EQT's exit strategy, clearing the path for potential monetization through IPO or trade sale discussions reportedly underway with advisers.
- • The CMA's investigation resulted in new industry rules including limits on first prescription charges and enhanced transparency requirements, though the regulator declined to impose broader price controls despite finding larger operators charged higher average prices than independent practices.
- • IVC Evidensia remains one of Europe's largest veterinary groups operating thousands of sites across multiple countries; the company reported modest revenue growth and mid-single-digit adjusted earnings growth, though statutory losses widened due to a Canadian operations write-down.
- • Exit discussions for EQT's investment have progressed to early-stage adviser engagement for a potential multibillion-pound London or European listing, though no final decision has been reached.
Summary
EQT's veterinary portfolio company IVC Evidensia has incurred substantial costs defending against regulatory scrutiny, spending £34m cumulatively over the past two years on a UK Competition and Markets Authority investigation. The Financial Times reported the figure based on newly filed accounts, revealing £10.6m in investigation-related and compliance costs during the year ended September 2025, compared to £24m expended in the prior 12-month period. This significant reduction in annual spend reflects the advancing stages of the regulatory process.
The CMA's conclusion of its industry-wide review of the UK veterinary sector in March 2026 represents a material development for EQT's exit planning. The investigation examined pricing practices across major veterinary chains and resulted in new regulatory requirements including limits on first prescription charges and mandated transparency enhancements. While the CMA determined that average prices at large operators exceeded those charged by independent practices, the regulator stopped short of imposing broader price controls across the sector, effectively limiting the scope of remedial actions imposed on IVC and its competitors.
The removal of this regulatory uncertainty clears a critical hurdle for EQT's previously constrained exit optionality. The firm has been evaluating multiple routes to liquidity, including a potential initial public offering or trade sale. According to the primary reporting, advisers have been engaged for early-stage discussions surrounding a multibillion-pound listing on London or European exchanges, though management has reached no definitive decision regarding timing or mechanism.
IVC Evidensia maintains its position as one of Europe's largest veterinary services operators, with thousands of sites spanning multiple geographies and a substantial international patient base. The company continues an active acquisition strategy while reinvesting in its existing network infrastructure. Financially, IVC demonstrated resilience with modest revenue expansion and mid-single-digit adjusted earnings growth, though reported statutory losses widened materially due to a significant write-down attributable to its Canadian operations division. This underlying operational stability, combined with the resolution of regulatory headwinds, positions the asset more favorably for potential exit execution.
The CMA's conclusion of its industry-wide review of the UK veterinary sector in March 2026 represents a material development for EQT's exit planning. The investigation examined pricing practices across major veterinary chains and resulted in new regulatory requirements including limits on first prescription charges and mandated transparency enhancements. While the CMA determined that average prices at large operators exceeded those charged by independent practices, the regulator stopped short of imposing broader price controls across the sector, effectively limiting the scope of remedial actions imposed on IVC and its competitors.
The removal of this regulatory uncertainty clears a critical hurdle for EQT's previously constrained exit optionality. The firm has been evaluating multiple routes to liquidity, including a potential initial public offering or trade sale. According to the primary reporting, advisers have been engaged for early-stage discussions surrounding a multibillion-pound listing on London or European exchanges, though management has reached no definitive decision regarding timing or mechanism.
IVC Evidensia maintains its position as one of Europe's largest veterinary services operators, with thousands of sites spanning multiple geographies and a substantial international patient base. The company continues an active acquisition strategy while reinvesting in its existing network infrastructure. Financially, IVC demonstrated resilience with modest revenue expansion and mid-single-digit adjusted earnings growth, though reported statutory losses widened materially due to a significant write-down attributable to its Canadian operations division. This underlying operational stability, combined with the resolution of regulatory headwinds, positions the asset more favorably for potential exit execution.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.